Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
Pathology and Treatment of Triple-Negative Breast Cancer
share announcement

Pathology and Treatment of Triple-Negative Breast Cancer

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Pathophysiology".

Deadline for manuscript submissions: 31 January 2026 | Viewed by 6788

Special Issue Editor

Dr. Ramadevi Subramani

E-Mail Website
Guest Editor
Center of Emphasis in Cancer Research, Department of Molecular and Translational Medicine, Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, TX 79905, USA
Interests: pancreatic, breast and liver cancer prevention and treatment; anti-cancer agents from natural products; tumor suppression; integrative cancer treatment; health care disparities; therapeutic/prognostic marker identification

Special Issue Information

Dear Colleagues,

We are pleased to announce the call for submissions to a Special Issue of the journal Cancers titled, 'Pathology and Treatment of Triple-Negative Breast Cancer'. Triple-negative breast cancer (TNBC) represents a distinct subtype of breast cancer characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression. This aggressive form of breast cancer poses significant challenges in diagnosis, treatment, and management.

This Special Issue aims to provide a comprehensive overview of the current knowledge and advancements in TNBC, from its underlying pathology to innovative treatment strategies. We invite researchers, clinicians, and experts in the field of breast cancer research and oncology to submit their original research articles, reviews, and clinical studies that cover various aspects of TNBC including, but not limited to, the following:

  1. Molecular and genetic profiling of TNBC;
  2. Novel biomarkers and diagnostic approaches;
  3. Insights into the tumor microenvironment and immune response;
  4. Targeted therapies and immunotherapies for TNBC;
  5. Advancements in surgical techniques and radiation therapy.

All submitted articles will undergo a rigorous peer review process to ensure their highest scientific quality and relevance to the field.

Should you have any questions, require further information, or need any assistance, please do not hesitate to contact us.

We look forward to receiving your submissions.

Dr. Ramadevi Subramani
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

15 pages, 5747 KiB  
Article
Significance of LIF/LIFR Signaling in the Progression of Obesity-Driven Triple-Negative Breast Cancer
by Lois Randolph, Jaitri Joshi, Alondra Lee Rodriguez Sanchez, Uday P. Pratap, Rahul Gopalam, Yidong Chen, Zhao Lai, Bindu Santhamma, Edward R. Kost, Hareesh B. Nair, Ratna K. Vadlamudi, Panneerdoss Subbarayalu and Suryavathi Viswanadhapalli
Cancers 2024, 16(21), 3630; https://doi.org/10.3390/cancers16213630 - 28 Oct 2024
Cited by 1 | Viewed by 1382
Abstract
American women with obesity have an increased incidence of triple-negative breast cancer (TNBC). The impact of obesity conditions on the tumor microenvironment is suspected to accelerate TNBC progression; however, the specific mechanism(s) remains elusive. This study explores the hypothesis that obesity upregulates leukemia [...] Read more.
American women with obesity have an increased incidence of triple-negative breast cancer (TNBC). The impact of obesity conditions on the tumor microenvironment is suspected to accelerate TNBC progression; however, the specific mechanism(s) remains elusive. This study explores the hypothesis that obesity upregulates leukemia inhibitory factor receptor (LIFR) oncogenic signaling in TNBC and assesses the efficacy of LIFR inhibition with EC359 in blocking TNBC progression. TNBC cell lines were co-cultured with human primary adipocytes, or adipocyte-conditioned medium, and treated with EC359. The effects of adiposity were measured using cell viability, colony formation, and invasion assays. Mechanistic studies utilized RNA-Seq, Western blotting, RT-qPCR, and reporter gene assays. The therapeutic potential of EC359 was tested using xenograft and patient-derived organoid (PDO) models. The results showed that adipose conditions increased TNBC cell proliferation and invasion, and these effects correlated with enhanced LIFR signaling. Accordingly, EC359 treatment reduced cell viability, colony formation, and invasion under adipose conditions and blocked adipose-mediated organoid growth and TNBC xenograft tumor growth. RNA-Seq analysis identified critical pathways modulated by LIF/LIFR signaling in diet-induced obesity mouse models. These findings suggest that adiposity contributes to TNBC progression via the activation of the LIF/LIFR pathway, and LIFR inhibition with EC359 represents a promising therapeutic approach for obesity-associated TNBC. Full article
(This article belongs to the Special Issue Pathology and Treatment of Triple-Negative Breast Cancer)
►▼ Show Figures

Figure 1

18 pages, 4426 KiB  
Article
Hypomethylation of ATP1A1 Is Associated with Poor Prognosis and Cancer Progression in Triple-Negative Breast Cancer
by Yesol Kim, Je Yeong Ko, Hyun Kyung Kong, Minyoung Lee, Woosung Chung, Sera Lim, Dasom Son, Sumin Oh, Jee Won Park, Do Yeon Kim, Minju Lee, Wonshik Han, Woong-Yang Park, Kyung Hyun Yoo and Jong Hoon Park
Cancers 2024, 16(9), 1666; https://doi.org/10.3390/cancers16091666 - 25 Apr 2024
Cited by 1 | Viewed by 1955
Abstract
Dysregulated DNA methylation in cancer is critical in the transcription machinery associated with cancer progression. Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype, but no treatment targeting TNBC biomarkers has yet been developed. To identify specific DNA methylation patterns in [...] Read more.
Dysregulated DNA methylation in cancer is critical in the transcription machinery associated with cancer progression. Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype, but no treatment targeting TNBC biomarkers has yet been developed. To identify specific DNA methylation patterns in TNBC, methyl-binding domain protein 2 (MBD) sequencing data were compared in TNBC and the three other major breast cancer subtypes. Integrated analysis of DNA methylation and gene expression identified a gene set showing a correlation between DNA methylation and gene expression. ATPase Na+/K+-transporting subunit alpha 1 (ATP1A1) was found to be specifically hypomethylated in the coding sequence (CDS) region and to show increased expression in TNBC. The Cancer Genome Atlas (TCGA) database also showed that hypomethylation and high expression of ATP1A1 were strongly associated with poor survival in patients with TNBC. Furthermore, ATP1A1 knockdown significantly reduced the viability and tumor-sphere formation of TNBC cells. These results suggest that the hypomethylation and overexpression of ATP1A1 could be a prognostic marker in TNBC and that the manipulation of ATP1A1 expression could be a therapeutic target in this disease. Full article
(This article belongs to the Special Issue Pathology and Treatment of Triple-Negative Breast Cancer)
►▼ Show Figures

Figure 1

Review

Jump to: Research

22 pages, 1119 KiB  
Review
Recent Developments in Combination Immunotherapy with Other Therapies and Nanoparticle-Based Therapy for Triple-Negative Breast Cancer (TNBC)
by Gantumur Battogtokh, Onyinyechi Obidiro and Emmanuel O. Akala
Cancers 2024, 16(11), 2012; https://doi.org/10.3390/cancers16112012 - 25 May 2024
Cited by 6 | Viewed by 2866
Abstract
Triple-negative breast cancer (TNBC), lacking specific receptors found in other breast cancer subtypes, poses significant treatment challenges due to limited therapeutic options. Therefore, it is necessary to develop novel treatment approaches for TNBC. In the last few decades, many attempts have been reported [...] Read more.
Triple-negative breast cancer (TNBC), lacking specific receptors found in other breast cancer subtypes, poses significant treatment challenges due to limited therapeutic options. Therefore, it is necessary to develop novel treatment approaches for TNBC. In the last few decades, many attempts have been reported for alternative tools for TNBC treatment: immunotherapy, radiotherapy, targeted therapy, combination therapy, and nanotechnology-based therapy. Among them, combination therapy and nanotechnology-based therapy show the most promise for TNBC treatment. This review outlines recent advancements in these areas, highlighting the efficacy of combination therapy (immunotherapy paired with chemotherapy, targeted therapy, or radiotherapy) in both preclinical and clinical stages and nanotechnology-based therapies utilizing various nanoparticles loaded with anticancer agents, nucleic acids, immunotherapeutics, or CRISPRs in preclinical stages for TNBC treatment. Full article
(This article belongs to the Special Issue Pathology and Treatment of Triple-Negative Breast Cancer)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop